Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
22 studies found for:    ocrelizumab
Show Display Options
Rank Status Study
1 Recruiting Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Ocrelizumab
2 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Ocrelizumab
3 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Ocrelizumab
4 Completed A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Ocrelizumab
5 Active, not recruiting A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: Ocrelizumab;   Other: Placebo
6 Completed A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Drug: ocrelizumab
7 Terminated A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Ocrelizumab;   Drug: Placebo
8 Active, not recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Ocrelizumab Placebo;   Drug: Rebif;   Drug: Rebif placebo
9 Active, not recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Ocrelizumab placebo;   Drug: Rebif;   Drug: Rebif placebo
10 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
11 Not yet recruiting Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Rituximab
12 Terminated A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
13 Terminated A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
14 Terminated A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
15 Terminated A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: placebo;   Drug: methotrexate;   Drug: ocrelizumabu 50mg;   Drug: ocrelizumabu 200mg;   Drug: ocrelizumab 500mg
16 Active, not recruiting A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
Condition: Rheumatoid Arthritis
Interventions: Drug: leflunomide;   Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
17 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
18 Active, not recruiting A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
Conditions: Lupus Nephritis;   Systemic Lupus Erythematosus
Interventions: Drug: corticosteroids;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: ocrelizumab;   Drug: placebo
19 Terminated A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: corticosteroids;   Drug: immunosuppressive regime;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
20 Active, not recruiting Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
Condition: Multiple Sclerosis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.